Robert Pitts in New York, New York

Home New York New York

Robert Pitts has Infectious Disease as his primary medical specialty. Their primary office is: 530 1st Ave in New York, New York. There is an additional office location, for a total of two, for Robert Pitts that can be viewed further down.

They're a part of the: New York University medical group which has around 4,291 members. You can call their office at 212-263-7300 to schedule an appointment. They also accept the Medicare-approved amount as payment in full. They attended University Of California, San Francisco School Of Medicine and graduated in 2013 (around 11 years of experience). They are not listed as doing telehealth appointments, but this may have changed. It can't hurt to call and check. If anything it may encourage them to make them available if they are not currently.

Robert Pitts Office Phone and Directions

Robert Pitts
New York University
530 1st Ave
New York, New York 10016
212-263-7300

Patient Ratings
Please rate your experience with Robert Pitts below to help others make a more informed decision. Thanks!

Current Rating: Loading...

Phone: 212-263-7300

Enter a starting address:

Healthcare Info for Robert Pitts

Medical School: University Of California, San Francisco School Of Medicine
Graduation Year: 2013
The Primary Medical Specialty for Robert Pitts is listed as: Infectious Disease
Approximate Years of Experience: 11
PAC (PECOS ID)#: 2163769530
NPI #: 1417299801
NPI Created On: 03/23/2013
NPI Last Updated Listed as: 09/08/2022
Primary Taxonomy Code: 207RI0200X
License Number:
280958
Listed Gender: Male

Open Payments Data. This can include items to test (Durable Medical Equipment (DME)), Biological, Drug Samples, etc. This data must be reported to CMS.

Payments Total: $53

Number of Payments:: 1

Form of Payment: In-kind items and services

Context of payment:: ;G2753576;CONCUR;12428569

Record ID:: 848259277

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: HIV

Name of Drug #1: Descovy

Open Associated Drug #1: 61958-2002-1